EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C

Marwan G Fakih, Lisa Salvatore iD, Taito Esaki, Dominik P Modest, David P Lopez-Bravo, Julien Taieb, Michalis V Karamouzis, Erika Ruiz-Garcia, Tae-Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham und 7 weitere

New England Journal of Medicine · 07.12.2023 · 389 (23) · 2125-2139

DOI: 10.1056/nejmoa2308795 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 07.12.2023. Verfasst von Marwan G Fakih und 18 weiteren Autor:innen. Beteiligte Einrichtung: From Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte (M.G.F.), and Amgen, Thousand Oaks (E.C., J.C., Y.S…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Colorectal Neoplasms. Die Arbeit wurde bisher 423-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsColorectal NeoplasmsHumansAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsErbB ReceptorsImmune Checkpoint InhibitorsMutationPanitumumabProto-Oncogene Proteins p21(ras)TrifluridinePhenylurea CompoundsPyridinesPiperazinesPyrimidinesPyrrolidinesThymine

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Agents, ImmunologicalErbB ReceptorsImmune Checkpoint InhibitorsPanitumumabProto-Oncogene Proteins p21(ras)TrifluridineKRAS protein, humanregorafenib

Autor:innen und Institutionen

  • From Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte (M.G.F.), and Amgen, Thousand Oaks (E.C., J.C., Y.S., Q.T.) - both in California; Oncologia Medica, Università Cattolica…

ORCID-Profile: Lisa Salvatore

Förderung

  • Amgen

Zitieren

APA

Fakih, M. G., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T. W., Kuboki, Y., Meriggi, F., Cunningham, D., Yeh, K. H., Chan, E., Chao, J., Saportas, Y., Tran, Q., Cremolini, C., & Pietrantonio, F. (2023). Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. New England Journal of Medicine, 389(23), 2125-2139. https://doi.org/10.1056/nejmoa2308795

Vancouver

Fakih MG, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, et al. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. New England Journal of Medicine. 2023;389(23):2125-2139. doi:10.1056/nejmoa2308795

BibTeX
@article{Fakih2023,
  author = {Fakih, Marwan G and Salvatore, Lisa and Esaki, Taito and Modest, Dominik P and Lopez-Bravo, David P and Taieb, Julien and Karamouzis, Michalis V and Ruiz-Garcia, Erika and Kim, Tae-Won and Kuboki, Yasutoshi and Meriggi, Fausto and Cunningham, David and Yeh, Kun-Huei and Chan, Emily and Chao, Joseph and Saportas, Yaneth and Tran, Qui and Cremolini, Chiara and Pietrantonio, Filippo},
  title = {Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {23},
  pages = {2125--2139},
  doi = {10.1056/nejmoa2308795}
}
Kostenlos starten →